Structure Therapeutics details positive trial data for a weight-loss pill, and the stock rockets
Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron, that just showed positive results from a Phase 2 trial.
Last updated: 2025-12-08 16:46:42 ET
Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron, that just showed positive results from a Phase 2 trial.
Artificial intelligence works fast, but its energy consumption is growing rapidly. A German-Taiwanese research team is now developing a solution: new memory for leading chip technologies smaller than 3 nm. These innovative nanosheet devices enable co...
Autonomous trucking is edging closer to commercial reality in the United States, but the companies leading the technology are finding that the real challenge is no longer just developing a safe self-driving system. It is building the ecosystem around...
For much of 2025, the frontier of open-weight language models has been defined not in Silicon Valley or New York City, but in Beijing and Hangzhou.Chi...